Oct 19 Update hints potential near term quarterly

New Post Public Reply Private Reply Replies (1) Message Board
solartech
532
Oct 19 Update hints potential near term quarterly revenue.

2017 Q1 (Jan-Mar) Financial Data

Assets: $1.7 million
Administration and R&D Expenses: $837K
Other Expense: $293K
Quarterly Loss: $1.16 million


(2017 Q2 (April-June) Report is mergered in 10K Annual Report)


As Online QD sale began only on August 23, there were only 5 weeks of sales for 2017 Q3 (July-Sept), but 2017 Q4 will report a full quarter of sales in February, 2018 and according to Stephen in the Oct 19 Update:

"We have begun to generate moderate revenues from our sale of quantum dot samples to our DISPLAY INDUSTRY customers. All indications are that these sales volumes will continue to increase and alone have the near term potential to cover a measurable portion of our monthly burn rate. Any additional sales realized from our point of sale efforts will enhance this further"

So, reading between the lines one can conceive that in the near term, Q4 QD sales to the Display Industry alone will be close to quarterly burn rate of $1.16 million. Our QD sales are mainly to DISPLAY INDUSTRY (such as TV makers), but additional sales to researchers and other innovative entrepreneurs will further enhance our sales revenue and could exceed our monthly burn rate, resulting in a positive earning.

It takes about one gram of QD for each TV panel, and TV makers will not be buying only a few grams. With 2017 TV shipment of 270 million units, QMC needs to capture only 1.5% of the market (4 million units) to reach the company's annual maximum production capacity of 4 tonnes (4,000 Kg, 4 million grams).

At maximum production capacity and annual sales and at humble, conservative variables as follow, projected share price will be:

QD sales in grams______ 4,000,000
QD sales price per gram_ $100
Gross sale ($)_________400,000,000
Profit margin__________40%
Net profit_____________ $160,000,000
Shares (fully diluted)____500,000,000
Net earning per share___0.3200
P/E ratio_____________10
Projected share price___$3.20




Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Adobe’s Recent Options Activity Results

Updated Category News Views 114

Adobe's Options Activity Highlights In the world of finance, significant trades often signal important market sentiments. Recently, major investors have moved toward a bearish outlook on Adobe. Analyzing the options history for Adobe (NASDAQ: ADBE), we've identified a total of 67 significant trades. Our insights reveal that approximately 41% of these trades have been...

Continue Reading
Indonesia's Ongoing Challenge with Chinese Maritime Presence

Updated Category News Views 130

Indonesia's Maritime Security Efforts Intensify Recently, Indonesia's maritime security has been under increased scrutiny as incidents involving a Chinese coast guard vessel continue to escalate. This week, a Chinese vessel was driven from Indonesian waters not once, but twice, after interfering with a critical energy survey conducted by Pertamina, the state energy...

Continue Reading
Revolutionizing Game Development with Upheaval Games' Dreamer Portal

Updated Category News Views 140

Welcome to the Future of Game Development Upheaval Games, founded by veterans from the gaming industry, embraces a new frontier in game design with the introduction of The Dreamer Portal. This innovative web-based interface allows creators to effortlessly build immersive game content with just a simple prompt. Imagine the power of crafting unique creatures, items, and...

Continue Reading
Alvotech Moves Forward with Gobivaz® Approval in Europe

Updated Category News Views 190

Alvotech and Advanz Pharma Collaborate for Biosimilar Approval REYKJAVIK and LONDON – Alvotech (NASDAQ: ALVO), a renowned biotechnology firm, along with Advanz Pharma, a leading global pharmaceutical company, has shared important news regarding the marketing approval of Gobivaz®, a proposed biosimilar to Simponi® (golimumab). This biologic treatment is designed for...

Continue Reading
Exploring the Growth Potential of Remote Patient Monitoring Sector

Updated Category News Views 181

Remote Patient Monitoring Set for Dynamic Growth The increasing prevalence of chronic conditions worldwide is expected to significantly accelerate the growth of the remote patient monitoring (RPM) market. As conditions like hypertension, diabetes, and cardiovascular diseases become more common, coupled with an aging population, healthcare systems face immense pressure to...

Continue Reading